Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.77 |
| ▸ | CTSS | P25774 | 2/20 | 0.77 |
| ▸ | SIRT2 | Q8IXJ6 | 14/20 | 0.59 |
| ▸ | SIRT1 | Q96EB6 | 11/20 | 0.59 |
| ▸ | SIRT3 | Q9NTG7 | 7/20 | 0.59 |
| ▸ | CTSK | P43235 | 2/20 | 0.56 |
| ▸ | TLR2 | O60603 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8767026 | 0.88 | CTSL (0.77) | CTSLCTSSSIRT2SIRT1SIRT3 | |
| SCHEMBL17889672 | 0.87 | SIRT5 (0.64) | CTSLCTSSSIRT2SIRT1SIRT3 | |
| SCHEMBL9516479 | 0.87 | SIRT2 (0.62) | CTSLCTSSSIRT2SIRT1SIRT3 | |
| SCHEMBL17889673 | 0.87 | SIRT5 (0.64) | CTSLCTSSSIRT2SIRT1SIRT3 | |
| SCHEMBL11737428 | 0.87 | CTSL (0.76) | CTSLCTSSSIRT2SIRT1SIRT3 | |
| SCHEMBL8766104 | 0.87 | CTSL (0.76) | CTSLCTSSSIRT2SIRT1SIRT3 | |
| SCHEMBL5934886 | 0.87 | CTSS (0.69) | CTSLCTSSCTSKCTSB | |
| SCHEMBL13884485 | 0.86 | CTSS (0.58) | CTSLCTSSCTSKCTSB | |
| SCHEMBL1122463 | 0.86 | CTSS (0.58) | CTSLCTSSCTSKCTSB | |
| SCHEMBL14433709 | 0.86 | CTSS (0.58) | CTSLCTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580852-B2 | 2-oxamide inhibitors of phospholipase A2 activity and cellular arachidonate release based on dipeptides and pseudopeptides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120095096-A1 | 2-OXAMIDE INHIBITORS OF PHOSPHOLIPASE A2 ACTIVITY AND CELLULAR ARACHIDONATE RELEASE BASED ON DIPEPTIDES AND PSEUDOPEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2010123832-A2 | 2-OXAMIDE INHIBITORS OF PHOSPHOLIPASE A2 ACTIVITY AND CELLULAR ARACHIDONATE RELEASE BASED ON DIPEPTIDES AND PSEUDOPEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095096-A1 | 2-OXAMIDE INHIBITORS OF PHOSPHOLIPASE A2 ACTIVITY AND CELLULAR ARACHIDONATE RELEASE BASED ON DIPEPTIDES AND PSEUDOPEPTIDES | PLA2G2E, PLA2G4A, PLAA | CTSL 924/4885CTSS 2394/4885SIRT2 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.